2024
Using Shame as a Signal to Talk about Suicide
Siegel J, Ko C. Using Shame as a Signal to Talk about Suicide. Clinical Chemistry 2024, 70: 786-788. PMID: 38441566, DOI: 10.1093/clinchem/hvae017.Peer-Reviewed Original Research
2021
Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
Siegel JD, Bhatia A, Ko CJ, Christensen SR. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab. JAAD Case Reports 2021, 18: 23-25. PMID: 34778502, PMCID: PMC8577130, DOI: 10.1016/j.jdcr.2021.10.009.Peer-Reviewed Original Research
2020
Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis
Hornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Development or worsening of sarcoidosis associated with IL‐17 blockade for psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2020, 34: e583-e585. PMID: 32277505, DOI: 10.1111/jdv.16451.Peer-Reviewed Case Reports and Technical NotesInterleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis
Wang A, Hornick N, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. Interleukin‐17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis. Journal Of The European Academy Of Dermatology And Venereology 2020, 34: e497-e499. PMID: 32249470, DOI: 10.1111/jdv.16416.Peer-Reviewed Case Reports and Technical Notes
2018
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy